Treatment for Herpes Simplex
For first clinical episodes of genital herpes, treat with oral acyclovir 400 mg three times daily for 5 days, or valacyclovir 500 mg twice daily for 5 days, or famciclovir 125 mg twice daily for 5 days 1.
First Clinical Episode
The initial outbreak requires prompt antiviral therapy to reduce symptom duration and viral shedding:
Recommended oral regimens:
- Acyclovir 400 mg three times daily for 5 days (most practical dosing)
- Acyclovir 200 mg five times daily for 5 days (less practical due to frequency)
- Acyclovir 800 mg twice daily for 5 days
- Valacyclovir 500 mg twice daily for 5 days (convenient dosing)
- Famciclovir 125 mg twice daily for 5 days (convenient dosing)
For first-episode herpes proctitis, use higher dosing: acyclovir 400 mg orally 5 times daily for 10 days 2.
For severe disease requiring hospitalization (disseminated infection, encephalitis, pneumonitis, hepatitis): acyclovir 5-10 mg/kg IV every 8 hours for 5-7 days or until clinical resolution 2, 1.
Recurrent Episodes
Episodic therapy is recommended only when started during prodrome or within 1 day of lesion onset 1. Most immunocompetent patients with recurrent disease do not benefit from treatment if started later 2.
Recommended episodic regimens (5-day course):
- Acyclovir 800 mg twice daily (most convenient)
- Acyclovir 400 mg three times daily
- Valacyclovir 500 mg twice daily
- Famciclovir 125 mg twice daily
The twice-daily regimens offer superior adherence compared to more frequent dosing 1.
Suppressive Therapy
Daily suppressive therapy reduces recurrence frequency by ≥75% and is indicated for patients with ≥6 recurrences per year 1.
Recommended suppressive regimens:
- Acyclovir 400 mg twice daily (proven safe for up to 6 years)
- Valacyclovir 500 mg once daily (most convenient, but less effective if ≥10 recurrences/year)
- Valacyclovir 1,000 mg once daily
- Famciclovir 250 mg twice daily
After 1 year of continuous suppressive therapy, discontinue to reassess recurrence rate, as frequency naturally decreases over time 1. Suppressive therapy does not eliminate asymptomatic viral shedding or completely prevent transmission 2, 1.
Special Populations
HIV-Infected Patients
Patients with HIV may require more aggressive therapy. For frequent or severe recurrences, daily suppressive therapy with oral acyclovir or famciclovir is recommended 3. Valacyclovir is also an option 3.
For acyclovir-resistant HSV (routinely cross-resistant to ganciclovir): use IV foscarnet or cidofovir 3.
Pregnant Women
Oral acyclovir prophylaxis during late pregnancy remains controversial and is not routinely recommended. However, for patients with frequent, severe recurrences of genital HSV, acyclovir prophylaxis may be indicated, as no pattern of adverse pregnancy outcomes has been reported after acyclovir exposure 3.
Critical Management Points
Avoid topical acyclovir - it is substantially less effective than oral therapy and its use is discouraged 2.
Patient counseling is essential:
- Abstain from sexual activity when lesions or prodromal symptoms are present 2, 1
- Use latex condoms during all sexual exposures to reduce transmission risk 3, 2
- Transmission can occur during asymptomatic periods through viral shedding 2, 1
- Women of childbearing age must inform prenatal care providers about HSV infection 2
Common pitfall: Starting episodic therapy too late. Patients should be provided with medication or a prescription in advance so treatment can begin at the first sign of prodrome or lesions 1.
Resistance consideration: Acyclovir-resistant strains have been isolated from patients on suppressive therapy but have not been associated with treatment failure in immunocompetent patients 2, 1. Resistance is more problematic in immunocompromised populations 2.
The evidence base consists primarily of CDC STD treatment guidelines from 1993-1998 2, 1, 2, 1, 2, with more recent guidance from 2022 4 confirming these approaches remain standard. While newer agents like helicase-primase inhibitors show promise 5, 6, acyclovir, valacyclovir, and famciclovir remain first-line therapy with decades of proven safety and efficacy.